Clinical Trial Detail

NCT ID NCT02392507
Title A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Nab-paclitaxel + Necitumumab

Age Groups: adult

No variant requirements are available.